<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168895</url>
  </required_header>
  <id_info>
    <org_study_id>14972</org_study_id>
    <secondary_id>2010-018521-19</secondary_id>
    <nct_id>NCT01168895</nct_id>
  </id_info>
  <brief_title>Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder</brief_title>
  <official_title>Randomized, Double-blind, Cross-over Study in COPD Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin&#xD;
      after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75&#xD;
      mg dose will be administered for the first time using a new high dose strength (i.e. one&#xD;
      capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. Safety investigations&#xD;
      will focus on local tolerability in the lung and evaluate whether the patient can inhale the&#xD;
      higher amount of powder compared to the lower dose strength. Pharmacokinetics is to see how&#xD;
      the body absorbs, distributes, breaks down and gets rid of the study drug. Results from this&#xD;
      study will be used to decide whether the new dose strength is suitable for larger clinical&#xD;
      trials planned for the COPD patients population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of ciprofloxacin pharmacokinetics derived from drug concentrations in blood, urine and sputum</measure>
    <time_frame>Within 24 hours after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Infection</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipro Inhale (Ciprofloxacin, BAYQ3939)</intervention_name>
    <description>32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipro Inhale (Ciprofloxacin, BAYQ3939)</intervention_name>
    <description>48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects with COPD, 40 - 75 years of age&#xD;
&#xD;
          -  All subjects must have a diagnosis of COPD and must have airway obstruction with a&#xD;
             post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of &gt;/= 30% and &lt;= 80% of&#xD;
             predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of &lt;/= 70%&#xD;
&#xD;
          -  Subjects must be current or ex-smokers with a smoking history of more than 10&#xD;
             pack-years&#xD;
&#xD;
          -  Subjects must be able to perform technically acceptable pulmonary function tests&#xD;
             during the study period as required in the protocol&#xD;
&#xD;
          -  Subjects must be able to produce an sufficient amount of sputum during sputum&#xD;
             induction at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a significant respiratory disease other than COPD.&#xD;
&#xD;
          -  Exacerbation within 8 weeks prior to screening&#xD;
&#xD;
          -  Subjects with more than 1 COPD exacerbation within 12 months prior to screening&#xD;
&#xD;
          -  Subjects must have an FEV1 of at least one Liter&#xD;
&#xD;
          -  Subjects with a history or physician's diagnosis of asthma. If a patient has a total&#xD;
             blood eosinophil count &gt;/= 0.6 x 10^9/L source documentation is required to verify&#xD;
             that the increased eosinophil count is related to a non-asthmatic condition.&#xD;
&#xD;
          -  Subjects with hypersensitivity to the ciprofloxacin or to other quinolones and/or to&#xD;
             inactive constituents of the inhalation powder&#xD;
&#xD;
          -  Subjects with known hypersensitivity of the bronchial system to inhalation of&#xD;
             nebulized drugs or saline solution&#xD;
&#xD;
          -  Subjects with a history of cystic fibrosis&#xD;
&#xD;
          -  Subjects with clinically evident bronchiectasis&#xD;
&#xD;
          -  Subjects taking any:&#xD;
&#xD;
               -  Oral beta-adrenergic drugs or non cardioselective beta blockers,&#xD;
&#xD;
               -  Oral glucocorticoids,&#xD;
&#xD;
               -  Antihistamines or antileukotrienes prescribed for asthma,&#xD;
&#xD;
               -  Oral cromolyn sodium or oral nedocromil sodium,&#xD;
&#xD;
               -  Concomitant inhalative therapy with antibiotics and / or concomitant systemic&#xD;
                  therapy with fluoroquinolones&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gro√ühansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>75 mg dose strength</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

